Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RAD 602

Drug Profile

RAD 602

Alternative Names: Lu177-labelled radiopharmaceutical theranostic; PTPµ-targeted theranostic; RAD-602

Latest Information Update: 03 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Case Western Reserve University School of Medicine
  • Developer Radiopharm Theranostics
  • Class Antineoplastics; Imaging agents; Peptides; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Glioblastoma

Most Recent Events

  • 17 Apr 2023 Radiopharm Theranostics enters into supply agreement with TerThera for Terbium-161 isotope to develop RAD 602
  • 09 Jun 2022 Radiopharm Theranostics plans a phase I trial in Glioblastoma during the fourth quarter of 2023
  • 09 Jun 2022 Radiopharm Theranostics sub-licenses PTPµ-targeted radiopharmaceutical agent from NeoIndicate
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top